NRG-BR007 (Table 2), also known as the “DEBRA” trial, is evaluating the omission of breast radiation following BCS in patients with stage 1, hormone receptor-positive, HER2-negative, breast cancer in patients with Oncotype recurrence scores (RS) ≤18. Here, ERBB2 is linked to breast carcinoma.